Lineage Cell Therapeutics (NYSE: LCTX) reported Q4 EPS of ($0.17), $0.12 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $1.2 million versus the consensus estimate of $640 thousand.

For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.